About 200 reports

  • MONOCLONAL ANTIBODIES IN CANCER TREATMENT, OPDIVO PERFORMANCE VS. INDUSTRY, 2010-2022
  • Scope and Methodology

XOLAIR (OMALIZUMAB) Chapter ##: Pipeline Disruptors: Asthma TABLE ##-##: LEADING ASTHMA PRODUCT SALES (GLOBAL), 2016 ($ IN MILLIONS) FIGURE ##-##: ASTHMA MARKET SHOWS CORTICOSTEROIDS TREATMENT OF CHOICE, SALES BY DRUG TYPE 2010-2016 ($ MILLIONS) Chapter ##: Pipeline Dis

  • Lymphoma
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

Gilead Sciences Disrupts HCV Market Figure ##-##: Gilead Sciences Dominates HCV Market, Displaces Current Therapies ($ millions) Bristol-Myers Squibb - Opdivo Disrupts Monoclonal Antibody Performance in Cancer Figure ##-##: Monoclonal Antibodies in Cancer Treatment, Opdivo

  • Leukemia
  • Lymphoma
  • Oncology
  • World
  • Market Size

PLoS One; ##(##): e## Kotsopoulos J, et al. (2010).

  • Lymphoma
  • World
  • AbbVie Inc.
  • Aduro BioTech, Inc.
  • Amgen Inc.
  • 7.3. FORECAST METHODOLOGY
  • XENCOR

THE DRUG IS CURRENTLY BEING DEVELOPED IN PHASE III FOR ASTHMA AND COPD.

  • Lymphoma
  • North America
  • United States
  • MedImmune, LLC
  • Roche Group

SR ONE ##.

  • Lymphoma
  • China
  • Celgene Corporation
  • Juno Therapeutics Inc.
  • Novartis AG
  • DRUGS BASED ON XMAB® ANTIBODY TECHNOLOGY

THIS DRUG HAS NOW REACHED PHASE III OF CLINICAL DEVELOPMENT FOR THE TREATMENT OF ASTHMA AND COPD., ##. ##. ##. ##. ##.

  • Lymphoma
  • North America
  • United States
  • Amgen Inc.
  • MedImmune, LLC
  • C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Discontinued Products
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Dormant Products

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H1 2018 Summary C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation....

  • Lymphoma
  • Therapy
  • United States
  • World
  • Kyowa Hakko Kirin Co., Ltd.
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Dormant Products
  • Pipeline by FLX Bio Inc, H2 2018

It was also under development for asthma, peripheral T-cell lymphoma, and allergic rhinitis.

  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • Kyowa Hakko Kirin Co., Ltd.
  • PERIPHERAL T-CELL LYMPHOMAS (PTCL)
  • PIPELINE BY SAREUM HOLDINGS PLC, H2 2018

It is also developing new approaches to the treatment of asthma.

  • Hospital
  • Lymphoma
  • United States
  • Product Initiative
  • Incyte Corporation

IT IS ALSO WORTH HIGHLIGHTING THAT IMMUNOTHERAPY IS BEING STUDIED NOT ONLY TO TREAT CANCER, BUT ALSO FOR SEVERAL OTHER INDICATIONS INCLUDING ASTHMA, ALLERGY AND ALZHEIMER' S DISEASE.

  • Lymphoma
  • North America
  • United States
  • Juno Therapeutics Inc.
  • Kite Pharma, Inc.
  • Follicular Lymphoma
  • PIPELINE BY AB SCIENCE SA, H1 2018

The study lasted for ## year.

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • MORPHOSYS RAISES USD124.3 MILLION IN PRIVATE PLACEMENT OF SHARES
  • MORPHOSYS COMPLETES PRIVATE PLACEMENT OF SHARES FOR US$112.7 MILLION

Two patients (one PR, one stable disease SD) discontinued due to adverse events.

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • United States
  • MorphoSys AG

As part of the randomized, double-blind, multicentre trial, patients were randomized in a ##:##:## ratio to receive PF- ##, PF-## or placebo.

  • Lymphoma
  • United States
  • World
  • Product Initiative
  • Pfizer Inc.

The company' s pipeline products comprise therapies such as SP-##-##, SP-##-##, SP-##-## and SP-##-##.

  • Cancer
  • Lymphoma
  • United States
  • World
  • Product Initiative
  • DORMANT PRODUCTS, H2 2017
  • Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria.

As of May 2013, it was a preclinical stage of development for asthma and COPD.

  • Lymphoma
  • United States
  • Company
  • Company Operations
  • Product Initiative

The company' s pipeline products comprise therapies such as SP-##-##, SP-##-##, SP-##-## and SP-##-##.

  • Lymphoma
  • Oncology
  • United States
  • World
  • Acetylon Pharmaceuticals, Inc.
  • Multiple Myeloma (Kahler Disease)
  • duvelisib

As of September 2014, it was in phase II stage of development for mild allergic asthma.

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • BAYER AG
  • PIPELINE BY ASTRAZENECA PLC, H1 2018

It is also developing new approaches to the treatment of asthma.

  • Cancer
  • Lymphoma
  • Therapy
  • World
  • Product Initiative
  • PIPELINE BY CURIS INC, H1 2018

Inhibition of IRAK## activity has been implicated in multiple diseases including rheumatoid arthritis, systemic lupus erythematosus, gout, inflammatory bowel disease, asthma, and allergic rhinitis.

  • Lymphoma
  • Therapy
  • United States
  • World
  • Product Initiative

Patients will be randomized ##:##:## to one of three arms: CABOMETYX and Opdivo; CABOMETYX, Opdivo and Yervoy; or sunitinib.

  • Lymphoma
  • Renal Cancer
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company

SUGGEST THAT LC##-## COULD BE A POTENTIAL THERAPEUTIC FOR BRONCHIAL ASTHMA.

  • Healthcare
  • Lymphoma
  • Monoclonal Antibody
  • United States
  • Product Initiative

SUGGEST THAT LC##-## COULD BE A POTENTIAL THERAPEUTIC FOR BRONCHIAL ASTHMA.

  • Cell Therapy
  • Lymphoma
  • Specialty Hospital
  • Transplantation
  • Pluristem Therapeutics Inc.
  • AB-8779 - DRUG PROFILE

It is also developing new approaches to the treatment of asthma.

  • Leukemia
  • Lymphoma
  • United States
  • Product Initiative
  • Celgene Corporation
  • PIPELINE BY ASTRAZENECA PLC, H1 2018

It is also developing new approaches to the treatment of asthma.

  • Cancer
  • Lymphoma
  • United States
  • Product Initiative
  • Idera Pharmaceuticals, Inc.

The company' s pharmaceutical products comprises of inhaled corticosteroid for asthma, osteoporosis drugs, anti-hyperuricemia agent, and others.

  • Lymphoma
  • Therapy
  • United States
  • World
  • Product Initiative

A Phase II randomized, double blind, placebo-controlled, crossover study to evaluate the safety and efficacy of eculizumab in subjects with mild allergic asthma was initiated in September 2007.

  • Lymphoma
  • Mental Health
  • United States
  • Product Initiative
  • Alexion Pharmaceuticals, Inc.

The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Unknown stages are ##, ##, ##, ## and ## respectively.

  • Hospital
  • Lymphoma
  • United States
  • World
  • Product Initiative

Its pharmaceutical products comprise inhaled corticosteroid for asthma, osteoporosis drugs, anti-hyperuricemia agent, and others.

  • Autoimmune Disease
  • Lymphoma
  • United States
  • World
  • Product Initiative
  • Non-Small Cell Lung Cancer
  • DEPRESSIVE DISORDER

Johnson & Johnson - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Johnson & Johnson - Product Pipeline Review - 2016’, provides an overview of the Johnson & Johnson’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development...

  • Infectious Disease
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • United States
  • PIPELINE BY ASCENTAGE PHARMA GROUP CORP LTD, H2 2018

It is also developing new approaches to the treatment of asthma.

  • Lymphoma
  • Therapy
  • United States
  • World
  • AbbVie Inc.